A peer-reviewed journal that offers evidence-based clinical information and continuing education for dentists.

Moderna Seeks Approval for Use of its COVID-19 Vaccine Among Kids Ages 12-17


Recently released data show that the Moderna COVID-19 vaccine is effective among children ages 12 to 17. Data were collected from a clinical trial of more than 3,700 adolescents. Among those who received two doses of the Moderna vaccine, no cases of COVID-19 were reported, which shows an efficacy rate of 100%. Moderna will seek Emergency Use Authorization to expand the vaccine’s reach to those ages 12 to 17. Currently, the Pfizer vaccine is the only COVID-19 immunization authorized for use in this age group. Click here to read more.

Leave A Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy